AOAmanda K. Ombrello

Amanda K. Ombrello

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amanda K. Ombrello has a total of 459 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Biologic–biologic and biologic–JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases

    by Abdurrahman Tufan, Deborah L. Stone, Tina Romeo, Patrycja Hoffmann, Lorena Wilson, Natalie T. Deuitch, Christina Kozycki, Kalpana Manthiram, Sarah Hansen, Daniel L. Kastner, et al.

  • Top Cited Papers

    Evaluation and Management of Deficiency of Adenosine Deaminase 2

    by Pui Y. Lee, Brad A. Davidson, Roshini S. Abraham, Blanche Alter, Juan I. Arostegui, Katherine Bell, Alexandre Belot, Jenna R. E. Bergerson, Timothy J. Bernard, Paul A. Brogan, et al.

    Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease characterized by systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency.1,2 DADA2 is caused by biallelic pathogenic variants in the ADA2 gene (formerly known as CECR1) on chromosome 22q11.3 This condition was first described in 2014 and more than 400 cases have been published to date.4,5 While affected individuals were mostly young children in the early case series, adult-onset cases of DADA2 are increasingly recognized.6,7 Based on population genetics, the aggregate carrier frequency of deleterious ADA2 variants is approximately 1 in 236 individuals, which translates into an estimated disease prevalence of 1 case per 222 000 individuals.8 This estimate makes DADA2 a rare disease according to the US Food and Drug Administration.9 However, such prevalence also establishes DADA2 as a more common monogenic autoinflammatory diseases with an estimated 35 000 affected individuals worldwide.8


  • Next generation sequencing panel screening of 320 patients with clinically unclassified systemic autoinflammatory diseases

    by Oskar Schnappauf, Hongying Wang, Natalie Deuitch, Natalia Sampaio Moura, Sofia Rosenzweig, Daniela Ospina Cardona, Patrycja Hoffmann, Deborah Stone, Amanda Ombrello, Daniel Kastner, et al.

  • DADA2

    by Amanda K. Ombrello

  • Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients

    by Kazusa Ishii, Marie Pouzolles, Christopher D. Chien, Rebecca A. Erwin-Cohen, M. Eric Kohler, Haiying Qin, Haiyan Lei, Skyler Kuhn, Amanda K. Ombrello, Alina Dulau-Florea, et al.

    Late-onset inflammatory toxicities resembling hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) occur after chimeric antigen receptor T cell (CAR T cell) infusion and represent a therapeutic challenge. Given the established link between perforin deficiency and primary HLH, we investigated the role of perforin in anti-CD19 CAR T cell efficacy and HLH-like toxicities in a syngeneic murine model. Perforin contributed to both CD8+ and CD4+ CAR T cell cytotoxicity but was not required for in vitro or in vivo leukemia clearance. Upon CAR-mediated in vitro activation, perforin-deficient CAR T cells produced higher amounts of proinflammatory cytokines compared with WT CAR T cells. Following in vivo clearance of leukemia, perforin-deficient CAR T cells reexpanded, resulting in splenomegaly with disruption of normal splenic architecture and the presence of hemophagocytes, which are findings reminiscent of HLH. Notably, a substantial fraction of patients who received anti-CD22 CAR T cells also experienced biphasic inflammation, with the second phase occurring after the resolution of cytokine release syndrome, resembling clinical manifestations of HLH. Elevated inflammatory cytokines such as IL-1β and IL-18 and concurrent late CAR T cell expansion characterized the HLH-like syndromes occurring in the murine model and in humans. Thus, a murine model of perforin-deficient CAR T cells recapitulated late-onset inflammatory toxicities occurring in human CAR T cell recipients, providing therapeutically relevant mechanistic insights.


  • Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease

    by Najoua Lalaoui, Steven E. Boyden, Hirotsugu Oda, Geryl M. Wood, Deborah L. Stone, Diep Chau, Lin Liu, Monique Stoffels, Tobias Kratina, Kate E. Lawlor, et al.

    RIPK1 is a key regulator of innate immune signalling pathways. To ensure an optimal inflammatory response, RIPK1 is regulated post-translationally by well-characterized ubiquitylation and phosphorylation events, as well as by caspase-8-mediated cleavage1,2,3,4,5,6,7. The physiological relevance of this cleavage event remains unclear, although it is thought to inhibit activation of RIPK3 and necroptosis8. Here we show that the heterozygous missense mutations D324N, D324H and D324Y prevent caspase cleavage of RIPK1 in humans and result in an early-onset periodic fever syndrome and severe intermittent lymphadenopathy—a condition we term ‘cleavage-resistant RIPK1-induced autoinflammatory syndrome’. To define the mechanism for this disease, we generated a cleavage-resistant Ripk1D325A mutant mouse strain. Whereas Ripk1−/− mice died postnatally from systemic inflammation, Ripk1D325A/D325A mice died during embryogenesis. Embryonic lethality was completely prevented by the combined loss of Casp8 and Ripk3, but not by loss of Ripk3 or Mlkl alone. Loss of RIPK1 kinase activity also prevented Ripk1D325A/D325A embryonic lethality, although the mice died before weaning from multi-organ inflammation in a RIPK3-dependent manner. Consistently, Ripk1D325A/D325A and Ripk1D325A/+ cells were hypersensitive to RIPK3-dependent TNF-induced apoptosis and necroptosis. Heterozygous Ripk1D325A/+ mice were viable and grossly normal, but were hyper-responsive to inflammatory stimuli in vivo. Our results demonstrate the importance of caspase-mediated RIPK1 cleavage during embryonic development and show that caspase cleavage of RIPK1 not only inhibits necroptosis but also maintains inflammatory homeostasis throughout life.


  • Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20

    by Daniella Muallem Schwartz, Sarah A Blackstone, Natalia Sampaio-Moura, Sofia Rosenzweig, Aarohan M Burma, Deborah Stone, Patrycja Hoffmann, Anne Jones, Tina Romeo, Karyl S Barron, et al.


  • Open Access

    Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2

    by Carmelo Carmona-Rivera, Sami S. Khaznadar, Kyawt W. Shwin, Jorge A. Irizarry-Caro, Liam J. O’nEil, Yudong Liu, Kenneth A. Jacobson, Amanda K. Ombrello, Deborah L. Stone, Wanxia L. Tsai, et al.

    Reduction of adenosine deaminase 2 (ADA2) activity due to autosomal-recessive loss-of-function mutations in the ADA2 gene (previously known as CECR1) results in a systemic vasculitis known as deficiency of ADA2 (DADA2). Neutrophils and a subset of neutrophils known as low-density granulocytes (LDGs) have been implicated in the pathogenesis of vasculitis, at least in part, through the formation of neutrophil extracellular traps (NETs). The study objective was to determine whether neutrophils and NETs play a pathogenic role in DADA2. In vivo evidence demonstrated NETs and macrophages in affected gastrointestinal tissue from patients with DADA2. An abundance of circulating LDGs prone to spontaneous NET formation was observed during active disease in DADA2 and were significantly reduced after remission induction by anti–tumor necrosis factor (TNF) therapy. Increased circulating LDGs were identified in unaffected family members with monoallelic ADA2 mutations. Adenosine triggered NET formation, particularly in neutrophils from female patients, by engaging A1 and A3 adenosine receptors (ARs) and through reactive oxygen species– and peptidylarginine deiminase–dependent pathways. Adenosine-induced NET formation was inhibited by recombinant ADA2, A1/A3 AR antagonists, or by an A2A agonist. M1 macrophages incubated with NETs derived from patients with DADA2 released significantly greater amounts of TNF-α. Treatment with an A2AAR agonist decreased nuclear translocation of NF-κB and subsequent production of inflammatory cytokines in DADA2 monocyte-derived macrophages. These results suggest that neutrophils may play a pathogenic role in DADA2. Modulation of adenosine-mediated NET formation may contribute a novel and directed therapeutic approach in the treatment of DADA2 and potentially other inflammatory diseases.


  • Treatment Strategies for Deficiency of Adenosine Deaminase 2

    by Amanda K. Ombrello, Jing Qin, Patrycja M. Hoffmann, Parag Kumar, Deborah Stone, Anne Jones, Tina Romeo, Beverly Barham, Gineth Pinto-Patarroyo, Camilo Toro, et al.

    The manifestations of a deficiency of adenosine deaminase 2, a genetic disease, include early-onset lacunar stroke. In a series of 15 patients with this disorder, treatment with a TNF inhibitor resulted in a reduction from 37 strokes to no strokes during 733 patient-months.